Pharmaceutical industry: 2023 in retrospect
European Pharmaceutical Review
JANUARY 29, 2024
During 2023, there were five revisions to the European Medicines Agency ’s (EMA’s) Questions and Answers (Q&As) for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products. 02 October 2023 EMA/409815/2020 Rev.19.
Let's personalize your content